Global Cancer Particle Therapy Market Growth (Status and Outlook) 2025-2031

The global Cancer Particle Therapy market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Cancer particle therapy, also known as particle beam therapy, is an advanced form of cancer treatment that uses charged particles, such as protons or heavy ions, to irradiate and target cancer cells.

United States market for Cancer Particle Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Cancer Particle Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Cancer Particle Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Cancer Particle Therapy players cover IBA Worldwide, Varian Medical Systems, Hitachi, Mevion Medical Systems, Proton Therapy Systems, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Cancer Particle Therapy Industry Forecast” looks at past sales and reviews total world Cancer Particle Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Cancer Particle Therapy sales for 2025 through 2031. With Cancer Particle Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Particle Therapy industry.

This Insight Report provides a comprehensive analysis of the global Cancer Particle Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cancer Particle Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Particle Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Particle Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Particle Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Particle Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Proton Therapy
Heavy-Ion Therapy

Segmentation by Application:
Hospital
Research institute

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
IBA Worldwide
Varian Medical Systems
Hitachi
Mevion Medical Systems
Proton Therapy Systems
BioSig Technologies
Canon Medical Systems
Provision Healthcare
Optivus Proton Therapy
ProTom International
AVO
Danfysik
P-CURE
ELKETA

Please note: The report will take approximately 2 business days to prepare and deliver.